Merck, Inc.
🇺🇸United States
A Multiple Dose Titration Study of MK-8892 in Participants With Pulmonary Hypertension and Left Heart Disease (MK-8892-007)
- First Posted Date
- 2014-03-05
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 4
- Registration Number
- NCT02078557
Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 22
- Registration Number
- NCT02076100
Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 36
- Registration Number
- NCT02064920
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
Phase 3
Completed
- Conditions
- Varicella
- Interventions
- Biological: VARIVAX™ New Seed ProcessBiological: VARIVAX™ 2007 processBiological: M-M-R II™
- First Posted Date
- 2014-02-13
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 611
- Registration Number
- NCT02062502
Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)
Phase 3
Completed
- Conditions
- Rotavirus Gastroenteritis
- Interventions
- Biological: V260Biological: Placebo to V260Biological: OPVBiological: DTaP
- First Posted Date
- 2014-02-13
- Last Posted Date
- 2018-11-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 4040
- Registration Number
- NCT02062385
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 531
- Registration Number
- NCT02059187
A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)
Phase 3
Completed
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 508
- Registration Number
- NCT02059161
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)
Phase 1
Completed
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 76
- Registration Number
- NCT02059174
A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: MK-8521 100μgDrug: MK-8521 300μgDrug: MK-8521 150μgDrug: MK-8521 50/72μgDrug: MK-8521 125μgDrug: MK-8521 35μgDrug: PlaceboDrug: MK-8521 175μgDrug: MK-8521 100/150μgDrug: MK-8521 125/150μgDrug: MK-8521 72/125μgDrug: MK-8521 200μg
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2020-07-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 61
- Registration Number
- NCT02055547
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
Phase 1
Completed
- Conditions
- Solid Tumor
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2014-02-04
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 477
- Registration Number
- NCT02054806
© Copyright 2025. All Rights Reserved by MedPath